Juvederm Ultra 3 with Lidocaine
Hybrid cross-linked hyaluronic acid dermal filler with 24mg/ml HA concentration and 0.3% lidocaine for mid-to-deep dermal implantation
VYCROSS™ Technology & Biocompatible Formulation
Juvederm Ultra 3 utilizes proprietary VYCROSS™ technology combining 50% high-molecular-weight (1,000 kDa) and 50% low-molecular-weight (20 kDa) hyaluronic acid chains. This creates a biphasic monophasic gel with optimal elasticity (G’ = 240 Pa) and viscosity (η* = 50 Pa·s) for natural tissue integration. Clinical studies demonstrate 92% patient satisfaction at 6 months post-treatment.
Key Clinical Advantages
Wrinkle Filling Performance
85% improvement in nasolabial fold severity (WSRS) at 12 months in multicenter RCT
Lip Enhancement
1.6mm mean vertical lip height increase with natural feel (6-month follow-up)
Patient Comfort
73% reduction in procedural pain scores compared to non-lidocaine formulations
Product Specifications
- Hyaluronic Acid: 24mg/ml cross-linked
- Needles: 4×27G 1/2″ (0.4×13mm)
- Packaging: 2×1ml sterile glass syringes
- pH: 6.8-7.4 (physiological range)
- Storage: 15-25°C (do not freeze)
- Shelf Life: 24 months unopened
Injection Protocol
- Needle: 27G 1/2″ at 30° angle
- Depth: Mid-to-deep dermis
- Technique: Linear threading or serial puncture
- Max Volume: 1ml per session
- Touch-up: ≥2 weeks post-treatment
Clinical Applications
Nasolabial Folds
Grade 2-4 folds: Use retrograde linear technique with 0.4-0.8ml per side. Apply digital molding post-injection.
Marionette Lines
0.2-0.4ml per side using vertical depot technique. Combine with mentalis tox for optimal outcomes.
Lip Enhancement
Vermillion border: 0.1-0.2ml per quadrant. Body: 0.4-0.6ml total volume using fanning technique.
Important Safety Information
Notice: Individual results may vary based on skin type, age, and injection technique. Must be administered by licensed medical professionals. Contraindicated in patients with severe allergies, bleeding disorders, or active skin infections.
Common side effects include temporary swelling (68% incidence), erythema (54%), and pain (39%). Avoid NSAIDs 7 days pre-treatment. Hyaluronidase reversal protocol must be available during administration.
